These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 27068527)

  • 1. In Vitro and Ex Vivo Evaluations of Lipid Anti-Cancer Nanoformulations: Insights and Assessment of Bioavailability Enhancement.
    Jain AS; Dhawan VV; Sarmento B; Nagarsenker MS
    AAPS PharmSciTech; 2016 Jun; 17(3):553-71. PubMed ID: 27068527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights on Oral Drug Delivery of Lipid Nanocarriers: a Win-Win Solution for Augmenting Bioavailability of Antiretroviral Drugs.
    Nabi B; Rehman S; Baboota S; Ali J
    AAPS PharmSciTech; 2019 Jan; 20(2):60. PubMed ID: 30623263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid--an emerging platform for oral delivery of drugs with poor bioavailability.
    Chakraborty S; Shukla D; Mishra B; Singh S
    Eur J Pharm Biopharm; 2009 Sep; 73(1):1-15. PubMed ID: 19505572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral bioavailability: issues and solutions via nanoformulations.
    Pathak K; Raghuvanshi S
    Clin Pharmacokinet; 2015 Apr; 54(4):325-57. PubMed ID: 25666353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle.
    Harde H; Das M; Jain S
    Expert Opin Drug Deliv; 2011 Nov; 8(11):1407-24. PubMed ID: 21831007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
    Dahan A; Hoffman A
    J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-based nanoformulations for peptide delivery.
    Matougui N; Boge L; Groo AC; Umerska A; Ringstad L; Bysell H; Saulnier P
    Int J Pharm; 2016 Apr; 502(1-2):80-97. PubMed ID: 26899976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges in Oral Drug Delivery and Applications of Lipid Nanoparticles as Potent Oral Drug Carriers for Managing Cardiovascular Risk Factors.
    Okur NÜ; Siafaka PI; Gökçe EH
    Curr Pharm Biotechnol; 2021; 22(7):892-905. PubMed ID: 32753006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration.
    Gaba B; Fazil M; Ali A; Baboota S; Sahni JK; Ali J
    Drug Deliv; 2015; 22(6):691-700. PubMed ID: 24670099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced bioavailability of tripterine through lipid nanoparticles using broccoli-derived lipids as a carrier material.
    Li W; Zhang T; Ye Y; Zhang X; Wu B
    Int J Pharm; 2015 Nov; 495(2):948-55. PubMed ID: 26453780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel nanoemulsion based lipid nanosystems for favorable in vitro and in vivo characteristics of curcumin.
    Wan K; Sun L; Hu X; Yan Z; Zhang Y; Zhang X; Zhang J
    Int J Pharm; 2016 May; 504(1-2):80-8. PubMed ID: 27034002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular uptake and transcytosis of lipid-based nanoparticles across the intestinal barrier: Relevance for oral drug delivery.
    Neves AR; Queiroz JF; Costa Lima SA; Figueiredo F; Fernandes R; Reis S
    J Colloid Interface Sci; 2016 Feb; 463():258-65. PubMed ID: 26550783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanostructured lipid carriers versus microemulsions for delivery of the poorly water-soluble drug luteolin.
    Liu Y; Wang L; Zhao Y; He M; Zhang X; Niu M; Feng N
    Int J Pharm; 2014 Dec; 476(1-2):169-77. PubMed ID: 25280882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo fate of lipid-based nanoparticles.
    Qi J; Zhuang J; Lu Y; Dong X; Zhao W; Wu W
    Drug Discov Today; 2017 Jan; 22(1):166-172. PubMed ID: 27713035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid nanoparticles as vehicles for oral delivery of insulin and insulin analogs: preliminary ex vivo and in vivo studies.
    Muntoni E; Marini E; Ahmadi N; Milla P; Ghè C; Bargoni A; Capucchio MT; Biasibetti E; Battaglia L
    Acta Diabetol; 2019 Dec; 56(12):1283-1292. PubMed ID: 31407113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement.
    Sanjula B; Shah FM; Javed A; Alka A
    J Drug Target; 2009 Apr; 17(3):249-56. PubMed ID: 19255893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro/in-vivo characterization of trans-resveratrol-loaded nanoparticulate drug delivery system for oral administration.
    Singh G; Pai RS
    J Pharm Pharmacol; 2014 Aug; 66(8):1062-76. PubMed ID: 24779896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles.
    Yuan H; Chen CY; Chai GH; Du YZ; Hu FQ
    Mol Pharm; 2013 May; 10(5):1865-73. PubMed ID: 23495754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous lipolysis/permeation in vitro model, for the estimation of bioavailability of lipid based drug delivery systems.
    Bibi HA; Holm R; Bauer-Brandl A
    Eur J Pharm Biopharm; 2017 Aug; 117():300-307. PubMed ID: 28478159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing intestinal drug solubilisation using lipid-based delivery systems.
    Porter CJ; Pouton CW; Cuine JF; Charman WN
    Adv Drug Deliv Rev; 2008 Mar; 60(6):673-91. PubMed ID: 18155801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.